Logo Image
News|Articles|March 15, 2016

Pharmaceutical Technology

  • Pharmaceutical Technology-03-15-2016
  • Volume 2016 eBook
  • Issue 1

Regulatory Considerations for Controlling Intermediates in Type-II Drug Master Files for the Manufacture of Generic Drug Substances

The authors present analysis of the state of control of intermediate identity and quality, based on analysis of recently submitted DMFs.

The authors present analysis of the state of control of intermediate identity and quality, based on analysis of recently submitted DMFs.

Read this article

from Pharmaceutical Technology’s 2016 Solid Dosage Drug Development and Manufacturing eBook.

View other articles in the

2016 Solid Dosage Drug Development and Manufacturing eBook.

Articles in this issue

over 10 years ago

Meeting USP Guidelines for Elemental Impurity Analysis with X-ray Fluorescence Spectrometry

over 10 years ago

Optimizing Tablet Compression

over 10 years ago

Excipient Quality and Selection

over 10 years ago

Filling the Analysis Gap in the Move to Continuous Processing

over 10 years ago

Modeling and Simulation Move Downstream

over 10 years ago

Unifying Excipient Databases

over 10 years ago

Establishing a New Performance Standard for HPMC Capsules

Related Content